Founder, Chairman and CEO
Jeffrey Wolf is founder and CEO of Heat Biologics. He also founded Seed-One Ventures, a firm focused on the systematic formation and management of new biomedical companies based upon breakthrough research.
Throughout his career, Mr. Wolf has specialized in building new life-science companies from the ground up and has played an active role in supporting the growth of his companies. Mr. Wolf's start-ups include Avigen (co-founder and director), a NASDAQ-listed gene therapy company; TyRx Pharma (co-founder and chairman), which was focused on the development of novel bio-compatible polymers and recently sold to Medtronic and EluSys Therapeutics (founder and CEO), focused on the development of novel antibodies against infectious diseases. Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. from the University of Chicago, where he graduated with honors in economics.
George Peoples, M.D., FACS
Chief Medical Advisor
U.S. Army, COL (ret) George E. Peoples, MD, FACS, serves as CMO for both Heat Biologics and its subsidiary, Pelican Therapeutics. Dr. Peoples is currently professor of surgery at Uniformed Services University of the Health Sciences, as well as adjunct professor of surgical oncology at MD Anderson Cancer Center (MDACC). He is also the founder and director of Cancer Insight, LLC, a clinical research and development organization dedicated to the discovering, development and testing for emerging biotechnologies specializing in cancer immunotherapy. Dr. Peoples recently retired from 30 years of active duty as a surgeon and as a research scientist in the military. He is the past chair of the cancer program at the San Antonio Military Medical Center, and the past deputy director of the United States Military Cancer Institute. Prior to that, he served as chief of surgical oncology at Walter Reed Amy Medical Center (WRAMC), as well as SAMMC. He is a graduate of the United States Military Academy, West Point and Johns Hopkins School of Medicine. Dr. Peoples completed his surgical training at Harvard's Brigham and Women's Hospital, and during that time, also completed a post-doctoral fellowship at the Laboratory of Biologic Cancer Therapy at Harvard Medical School. He then completed a surgical oncology fellowship at MDACC. Dr. Peoples has written extensively on the immune response to cancer, with over 300 peer-reviewed manuscripts, abstracts and book chapters.
Anthony Manning, Ph.D.
Chief Scientific Advisor
Dr. Manning brings over three decades of experience in immunology and autoimmune disease research and development. Most recently, Dr. Manning served as Chief Scientific Officer and Head of Research at Momenta Pharmaceuticals, a biotechnology company focused on biologic therapeutics to treat rare immune-mediated diseases. At Momenta, Dr. Manning provided strategic leadership to all research activities, including the discovery and development of three novel autoimmune drug candidates. Momenta was recently acquired by Johnson & Johnson for approximately $6.5 billion. Prior to Momenta, Dr. Manning served as Senior Vice President of Research and Preclinical Development at Aileron Therapeutics, where he oversaw target selection, lead identification and optimization, clinical candidate selection, and IND-enabling studies. Before Aileron, Dr. Manning served as Vice President and Head of Inflammation and Autoimmune Disease Research at Biogen, and previously served as Vice President and Global Therapy Area Head of Inflammation, Autoimmunity & Transplantation Research at Roche. Dr. Manning is a member of the Board Directors of Palatin Technologies, Inc, Chairman of the Institute for Biomedical Entrepreneurship, and an Advisor to the Harvard Medical School Therapeutics Initiative. He is an author and inventor on over 120 publications and patents relating to autoimmune disease and novel drug discovery.
William L. Ostrander
Chief Financial Officer
Mr. Ostrander joined the Company in September 2019 as the Company’s Vice President of Finance and Secretary in September 2019. Mr. Ostrander has over 22 years of experience in financial management at public and private companies. From November 2014 until joining the Company, Mr. Ostrander served as Executive Director of Finance at Liquidia Technologies, a publicly-traded biopharmaceutical company. Prior to that, he served as Senior Director of Finance and Accounting at KBI Biopharma, a biopharmaceutical contract services company. He also served as Manager of Finance at LexisNexis Risk Solutions, a data analytics solutions company. Prior to that, he served as Controller of Seisint Inc., a private information products company that was acquired by LexisNexis. He also served as Senior Manager, Finance and held other accounting and finance positions for Boca Research, a data communications hardware manufacturer. Mr. Ostrander holds a B.S. in Finance from Central Michigan University.
Paul W. Tebbey, Ph.D., M.B.A.
Senior Vice President of Product Development and Portfolio Strategy
Paul Tebbey is a pharmaceutical development strategy leader with over 25 years of healthcare and management experience across the biotechnology and pharmaceutical sectors at companies such as Abbvie, Baxter, Centocor/Johnson & Johnson and Wyeth/Pfizer. Dr Tebbey’s research, development and commercial launch experiences include novel monoclonal antibodies (STELARA® first-in-IL-12/23 class, REMICADE® & HUMIRA® anti-TNF mAbs), complex vaccines (PREVNAR® novel conjugated vaccine, influenza and respiratory syncytial virus), biosimilars as well as targeted oncolytic small molecules (VENCLEXTA®). Dr Tebbey received a Ph.D., in Microbiology and Immunology from East Carolina University School of Medicine where his research focused on T lymphocyte cell signalling, immunosuppression and transformation. Subsequent to his postdoctoral studies at Vanderbilt University which focused on the regulation of gene expression, he then graduated with a MBA in Marketing from Rochester Institute of Technology. Dr Tebbey’s publications include over 40 peer-reviewed articles that span immunology, immune-mediated and infectious diseases, clinical trial design as well as pharmaceutical strategy planning and brand success.
Guillermo (Bill) Arana, MS
Vice President of Clinical Operations
As Executive Director of Clinical Development, Bill Arana oversees the strategic and operational aspects of clinical drug development for Heat Biologics and its subsidiaries.
Mr. Arana has over 20 years of experience in the pharmaceutical industry, holding director and management positions in clinical development and operations. At Emergo Therapeutics he worked on a novel immunological treatment for influenza like infection. While at Argos Therapeutics, Mr. Arana led the clinical department conducting a phase 3 clinical trial of an autologous cellular immunotherapy for oncology and was responsible for planning the clinical development strategy and regulatory authority interactions for the program. At Kowa Research Institute, he initiated the first clinical trial the company conducted in the United States and grew the Clinical Operations department. Prior to joining Kowa, he worked in CROs where he managed international clinical trials in infectious diseases for large and mid-sized pharmaceutical companies. Mr. Arana also worked at Trimeris, Inc. managing the conduct of the proof of concept trials for Fuzeon, the first fusion inhibitor approved to treat HIV infection. He began his career in clinical research as a CRA, working initially for a CRO and later as an independent contractor. Before entering the pharmaceutical industry, he worked as a senior research technician at Duke University Medical Center in the Bryan Alzheimer’s Disease Research Center.
Mr. Arana received an M.S. Degree in Molecular Biology and Biotechnology from East Carolina University and B.S. in Biology from the University of North Carolina at Chapel Hill.
Matthew M. Seavey, Ph.D.
Vice President of Research
As Senior Director of Research, Matthew Seavey, holds over a decade in preclinical drug development experience. Originally trained as an immunologist and an expert in early drug development, Matt has been involved in the development of different drug modalities (biologics, small molecules, cellular therapeutics, vaccines) across multiple therapeutic areas including, GI, CNS, immuno-oncology, respiratory, inflammation and cardio-metabolics. Matt has held former positions as Drug Discovery Team Leader at Cephalon, Global Pharmacology Project Leader at Teva Pharmaceuticals, and Oncology Program Director at United Therapeutics. Matt is a co-inventor on several patents and has contributed to the intellectual property base of Advaxis and founding of Oncoceutics. Most recently Matt was Director of Preclinical Pharmacology for CinRx Pharma and founding partner of BioPoint Consulting, LLC. Matt holds a BS in Microbiology from the University of Vermont, an MSc and PhD in Immunology from the University of Rochester and an MBA from West Chester University.
Vice President, Chemistry and Manufacturing Controls (CMC)
As Vice President of Chemistry and Manufacturing Controls, Gary Vinson is responsible for all manufacturing and analytical development for Heat Biologics, as well as for the company's subsidiary, Pelican Therapeutics. He has more than 20 years of experience in the pharmaceutical, CRO/CMO and biotechnology industries, in technical, development and quality roles. Prior to joining Heat, he held roles as Vice President, Pharmaceutical Development at a specialty pharmaceutical company, BioDelivery Sciences, and at Aldagen, a clinical-stage regenerative medicine company developing adult cell therapies. His responsibilities have included leading manufacturing, analytical development and quality organizations, and he has significant experience developing CDMO outsourcing relationships from pre-IND through to registration. Mr. Vinson founded and was Managing Partner of The Perdoceo Group, LLC, a consulting firm providing CMC support to biotechnology and pharmaceutical clients. He began his career with Glaxo, Inc. and worked at Magellan Laboratories, where he was a principal in establishing the pharmaceutics group to provide contract development and manufacturing of clinical trial materials. Mr. Vinson received his B.S. In Chemistry from North Carolina State University and holds CPGP (Certified GMP Professional) and RAC (Regulatory Affairs Certification) certifications.
Cheni Kwok, Ph.D., CLP
Senior Business Development Advisor
Dr. Kwok is a senior biopharmaceutical executive with broad operational expertise who has executed over 150 transactions including M&A, strategic partnerships, licensing, divestitures, spin-offs and project financing. Since 2011, Dr. Kwok is the Managing Partner and Founder of Linear Dreams LLC, a management consultancy for the life sciences industry. The firm engages a broad range of business and corporate development activities for 49 biopharmaceuticals companies, contract research & non-profit organizations, research institutes and investors in USA, Europe, China, Taiwan and Singapore.
As Senior Vice President, Corporate Development at Poniard Pharmaceuticals Inc., Dr. Kwok established corporate and business development, strategic and commercial planning, new product planning, competitive intelligence and forecasting functions. Previously, she was Director of Business Development at Celera Genomics Inc., where she led the business development efforts for Celera's small molecule therapeutics, including the divestiture of the oncology pipeline (including Imbruvica® (ibrutinib)) to Pharmacyclics Inc. (now an AbbVie Company). Dr. Kwok held business development positions of increasing responsibility at Exelixis Inc., where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline PLC (GSK) collaboration. Prior to joining Exelixis Inc., she held various research management, technology assessment and alliance management roles at SmithKline Beecham PLC (now GSK).
Dr. Kwok received a bachelor's degree with first class honors in biotechnology from the Imperial College of Science, Technology and Medicine, University of London, UK, a Ph.D. in human molecular genetics from the University of Cambridge, UK and has earned the Certified Licensing Professional (CLP) credential. At present, Dr. Kwok is serving as the Board of Directors of Chinese-American Biopharmaceutical Society (CABS) and serves on the Standards, Admissions & Recertification committee of Certified Licensing Professionals, Inc.